Table 2.
Subgroup analysis of HADS-A, HADS-D, and QLQ-C30 scores at M6 between UC group and RTC group.
| Items | Assessment at M6 | UC group | RTC group | p value |
|---|---|---|---|---|
| Time to recurrence | ||||
| <3 years | HADS-A score | 8.3 ± 2.8 | 5.1 ± 2.3 | 0.013 |
| HADS-D score | 6.6 ± 3.4 | 4.9 ± 1.6 | 0.170 | |
| QLQ-C30 global health status score | 65.1 ± 18.5 | 83.4 ± 11.1 | 0.017 | |
| QLQ-C30 function score | 65.0 ± 17.0 | 77.1 ± 13.0 | 0.096 | |
| QLQ-C30 symptoms score | 25.8 ± 16.0 | 22.3 ± 13.2 | 0.608 | |
| 3–5 years | HADS-A score | 6.2 ± 1.9 | 6.2 ± 2.2 | 0.988 |
| HADS-D score | 5.3 ± 2.0 | 5.2 ± 2.5 | 0.983 | |
| QLQ-C30 global health status score | 74.2 ± 11.4 | 75.7 ± 20.3 | 0.821 | |
| QLQ-C30 function score | 73.5 ± 10.3 | 75.1 ± 15.1 | 0.765 | |
| QLQ-C30 symptoms score | 26.1 ± 12.7 | 27.2 ± 14.9 | 0.839 | |
| ≥5 years | HADS-A score | 7.4 ± 2.7 | 5.1 ± 1.9 | 0.032 |
| HADS-D score | 7.4 ± 1.4 | 4.7 ± 2.6 | 0.009 | |
| QLQ-C30 global health status score | 64.6 ± 20.0 | 77.9 ± 16.0 | 0.102 | |
| QLQ-C30 function score | 64.6 ± 17.7 | 77.6 ± 16.0 | 0.084 | |
| QLQ-C30 symptoms score | 37.0 ± 17.8 | 24.2 ± 15.9 | 0.089 | |
| Distance metastases at recurrence | ||||
| No | HADS-A score | 7.2 ± 2.4 | 5.4 ± 1.9 | 0.009 |
| HADS-D score | 5.8 ± 2.0 | 4.6 ± 2.2 | 0.074 | |
| QLQ-C30 global health status score | 71.6 ± 16.1 | 79.8 ± 16.7 | 0.108 | |
| QLQ-C30 function score | 72.2 ± 14.2 | 77.6 ± 16.0 | 0.248 | |
| QLQ-C30 symptoms score | 27.6 ± 14.8 | 23.2 ± 15.6 | 0.353 | |
| Yes | HADS-A score | 7.3 ± 2.9 | 5.8 ± 2.5 | 0.185 |
| HADS-D score | 7.5 ± 3.0 | 5.6 ± 2.4 | 0.099 | |
| QLQ-C30 global health status score | 61.9 ± 17.3 | 76.4 ± 16.9 | 0.050 | |
| QLQ-C30 function score | 59.9 ± 14.8 | 74.6 ± 11.7 | 0.013 | |
| QLQ-C30 symptoms score | 33.2 ± 18.0 | 27.8 ± 12.4 | 0.408 | |
| Radiotherapy | ||||
| No | HADS-A score | 7.7 ± 2.5 | 5.1 ± 2.1 | 0.001 |
| HADS-D score | 6.4 ± 2.0 | 5.1 ± 2.4 | 0.073 | |
| QLQ-C30 global health status score | 67.5 ± 15.8 | 79.2 ± 16.9 | 0.026 | |
| QLQ-C30 function score | 66.5 ± 13.1 | 77.6 ± 15.0 | 0.014 | |
| QLQ-C30 symptoms score | 27.5 ± 12.0 | 23.8 ± 14.5 | 0.383 | |
| Yes | HADS-A score | 6.8 ± 2.7 | 6.6 ± 1.9 | 0.915 |
| HADS-D score | 6.4 ± 3.1 | 4.6 ± 2.0 | 0.127 | |
| QLQ-C30 global health status score | 68.9 ± 18.9 | 76.9 ± 16.6 | 0.308 | |
| QLQ-C30 function score | 69.5 ± 18.2 | 73.1 ± 13.0 | 0.612 | |
| QLQ-C30 symptoms score | 32.1 ± 10.1 | 27.7 ± 14.9 | 0.507 | |
| Targeted drug therapy | ||||
| No | HADS-A score | 7.8 ± 2.0 | 5.6 ± 2.5 | 0.034 |
| HADS-D score | 6.5 ± 2.0 | 5.4 ± 2.3 | 0.244 | |
| QLQ-C30 global health status score | 75.8 ± 14.2 | 77.5 ± 18.7 | 0.823 | |
| QLQ-C30 function score | 71.1 ± 15.6 | 73.1 ± 13.7 | 0.759 | |
| QLQ-C30 symptoms score | 28.0 ± 15.4 | 24.0 ± 13.6 | 0.523 | |
| Yes | HADS-A score | 7.0 ± 2.8 | 5.5 ± 2.0 | 0.041 |
| HADS-D score | 6.3 ± 2.7 | 4.8 ± 2.3 | 0.041 | |
| QLQ-C30 global health status score | 65.0 ± 17.3 | 79.1 ± 15.9 | 0.006 | |
| QLQ-C30 function score | 66.5 ± 15.4 | 78.2 ± 14.8 | 0.012 | |
| QLQ-C30 symptoms score | 30.2 ± 16.5 | 25.3 ± 15.2 | 0.307 | |
| ICI treatment | ||||
| No | HADS-A score | 7.0 ± 2.6 | 5.5 ± 1.9 | 0.024 |
| HADS-D score | 6.0 ± 2.3 | 4.9 ± 2.3 | 0.092 | |
| QLQ-C30 global health status score | 69.5 ± 16.2 | 81.5 ± 14.9 | 0.007 | |
| QLQ-C30 function score | 71.0 ± 13.6 | 78.0 ± 14.6 | 0.077 | |
| QLQ-C30 symptoms score | 28.3 ± 15.8 | 22.3 ± 14.7 | 0.160 | |
| Yes | HADS-A score | 8.1 ± 2.2 | 5.7 ± 2.9 | 0.100 |
| HADS-D score | 7.8 ± 2.8 | 5.3 ± 2.5 | 0.118 | |
| QLQ-C30 global health status score | 63.8 ± 19.8 | 65.3 ± 18.6 | 0.882 | |
| QLQ-C30 function score | 57.6 ± 17.3 | 69.7 ± 12.6 | 0.176 | |
| QLQ-C30 symptoms score | 33.6 ± 17.0 | 36.5 ± 4.8 | 0.697 | |
UC, usual care program; RTC, reminiscence therapy-based care program; ICI, immune check-point inhibitor; HADS-A, Hospital Anxiety and Depression Scale-anxiety; HADS-D, Hospital Anxiety and Depression Scale-depression; QLQ-C30, Quality of Life Questionnaire-Core 30; SD, standard deviation. All data are presented as mean ± SD.